Eylea growth slows a bit, but Regeneron hikes 2013 forecast

Tracy Staton

once again beat expectations with its quarterly earnings. And once again, the company raised its for , the vision-loss drug that's fueling much of its . But once again, said that sales growth for Eylea was slowing down as patients use fewer doses.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS